Using combination therapy to thwart drug resistance

Future Microbiology

Volumn 10, Issue 11, 2015, Pages 1719-1726

  Hill, Jessica A ^a   Cowen, Leah E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

antimicrobials; combination therapy; drug interactions; drug resistance; modeling drug resistance; resistance mechanisms

Indexed keywords

ADEP 4; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ARTEMISININ; CIPROFLOXACIN; DOXYCYCLINE; FLUCONAZOLE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; ANTIPARASITIC RESISTANCE; BACTERIAL GROWTH; BACTERIAL INFECTION; BIOFILM; BIOLUMINESCENCE; CANDIDA ALBICANS; CROSS RESISTANCE; DRUG COMBINATION; DRUG POTENTIATION; DRUG RESISTANCE; ESCHERICHIA COLI; FILOBASIDIELLA; GENE INTERACTION; HUMAN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; COMBINATION DRUG THERAPY; COMMUNICABLE DISEASES; PROCEDURES;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84948132726     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.68     Document Type: Review

References (28)

1. CDC. Antibiotic resistance threats in the United States, 2013 (2013).
2. Palumbi SR. Humans as the world's greatest evolutionary force. Science 293(5536), 1786-1790 (2001).
3. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5(2), 115-119 (2005).
4. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat. Rev. Drug Discov. 11(3), 171-172 (2012).
5. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7(12), 864-874 (2009).
6. Broder S. Twenty-five years of translational medicine in antiretroviral therapy: promises to keep. Sci. Transl. Med. 2(39), 39ps33 (2010).
7. Martinez JL. Antibiotics and antibiotic resistance genes in natural environments. Science 321(5887), 365-367 (2008).
8. D'costa VM, Mcgrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 311(5759), 374-377 (2006).
9. Drlica K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52(1), 11-17 (2003).
10. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36(1), 1-53 (2010).
11. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309(5744), 2185-2189 (2005).
12. Cowen LE. The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens. Cur. Opin. Microbiol. 16(4), 377-384 (2013).
13. Conlon BP, Nakayasu ES, Fleck LE et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503(7476), 365-370 (2013).
14. Miotto O, Almagro-Garcia J, Manske M et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat. Genet. 45(6), 648-655 (2013).
15. Lehar J, Stockwell BR, Giaever G, Nislow C. Combination chemical genetics. Nat. Chem. Biol. 4(11), 674-681 (2008).
16. Yeh P, Tschumi AI, Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38(4), 489-494 (2006).
17. Spitzer M, Griffiths E, Blakely KM et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7, 499 (2011).
18. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94(22), 12106-12111 (1997).
19. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R. Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7(6), 460-466 (2009).
20. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2(9), 458-466 (2006).
21. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin. Proc. 86(2), 156-167 (2011).
22. Chait R, Craney A, Kishony R. Antibiotic interactions that select against resistance. Nature 446(7136), 668-671 (2007).
23. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. Accelerated evolution of resistance in multidrug environments. Proc. Natl Acad. Sci. USA 105(37), 13977-13981 (2008).
24. Torella JP, Chait R, Kishony R. Optimal drug synergy in antimicrobial treatments. PLoS Comput. Biol. 6(6), e1000796 (2010).
25. Pena-Miller R, Laehnemann D, Jansen G et al. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biol. 11(4), e1001540 (2013).
26. Ostrosky-Zeichner L. Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect 14(Suppl. 4), 65-70 (2008).
27. Andersson DI, Hughes D.Antibiotic resistance and its cost: is it possible to reverse resistance Nat. Rev. Microbiol. 8(4), 260-271 (2010).
28. Hill JA, Ammar R, Torti D, Nislow C, Cowen LE. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet. 9(4), e1003390 (2013).